Company / SG&A Expense
Oric Pharmaceuticals, Inc. SG&A Expense History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$33.2M
FY2025
5-year range
$22.0M / $33.2M
FY2021-FY2025
Trend
+15.1%
vs FY2024
Sector context
#181 of 213
Health Care
What the data says
Oric Pharmaceuticals, Inc.'s sg&a expense of $33M is lower than 85% of companies in the Health Care sector (FY2025). SG&A Expense has increased for 7 consecutive years, from $3M in FY2018 to $33M in FY2025.
Based on SEC 10-K filings.
$33M in FY2025 with a 5-year CAGR of +19.8%.
Increased from $26M to $33M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +9.8%
- 5-Year CAGR
- +19.8%
- 10-Year CAGR
- -
Sector benchmark
Top 15% in Health CareTop 15% of 213This company $33.2M Sector average $722.3M
▼
-95.4% below sector average
Key checks
Key Insights
- Oric Pharmaceuticals, Inc.'s sg&a expense has grown for 7 consecutive years.
- 5-year CAGR of +19.8%, indicating consistent growth.
- In FY2025, sg&a expense increased 15.1% year-over-year.
- Ranks #181 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 5.96 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $33.2M | +15.1% |
| FY2024 | $28.8M | +12.6% |
| FY2023 | $25.6M | +2.1% |
| FY2022 | $25.1M | +14.0% |
| FY2021 | $22.0M | +64.0% |
| FY2020 | $13.4M | +134.4% |
| FY2019 | $5.7M | +71.2% |
| FY2018 | $3.3M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026